A Phase 2 Double-Blind, Placebo-Controlled Multi-dose Study to Investigate Etokimab (ANB020) Activity in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Etokimab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- Acronyms ECLIPSE
- Sponsors AnaptysBio
- 08 Nov 2019 According to an AnaptysBio media release, the Company anticipates topline data from an interim analysis of the ECLIPSE trial in the first quarter of 2020.
- 30 Jan 2019 Status changed from not yet recruiting to recruiting.
- 13 Aug 2018 New trial record